24-dihydrolanosterol | 911660-54-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 24-dihydrolanosterol
• 英文别名: dihydrolanosterol；Lanosterol, 24,25-dihydro-；(3S,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 911660-54-3
• 化学式: C₃₀H₅₂O
• 分子量: 428.742
• InChiKey: MBZYKEVPFYHDOH-XCEBNUDKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.4
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  氯 2,3,4,6-四-O-苄基-|á-D-吡喃葡萄糖苷 、 24-dihydrolanosterol 生成 (3R,4S,5R,6R)-2-[[(3S,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxane
  参考文献：
  名称：

  NISHIZAWA, MUGIO;KAN, YUKIKO;YAMADA, HIDETOSHI, CHEM. AND PHARM. BULL., 37,(1989) N, C. 565-567

  摘要：

  DOI：

文献信息

• [EN] PROCESS FOR THE PREPARATION OF LANOSTA-8-ENE COMPOU<br/>[FR] PROCÉDÉ DE PRÉPARATION DE COMPOSÉS LANOSTA-8-ÈNES
  申请人：AMAZONIA FITOMEDICAMENTOS LTDA

  公开号：WO2010015875A1

  公开（公告）日：2010-02-11

  The present invention concerns a process for the preparation of lanosta-8-ene compounds having lanosta-8-ene-7-one or lanosta-8-ene-7-ol compounds as starting material.

  本发明涉及一种以lanosta-8-ene-7-one或lanosta-8-ene-7-ol化合物为起始原料制备lanosta-8-ene化合物的方法。
• CRYSTAL FORM OF LANOSTEROL PRODRUG COMPOUND AND APPLICATION THEREOF
  申请人：GUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO., LTD.

  公开号：US20210246158A1

  公开（公告）日：2021-08-12

  The present invention relates to a crystal form of a compound of formula (I) and an application thereof in preparing a drug for treating an ophthalmic disease.

  本发明涉及一种化合物（I）的晶体形式及其在制备用于治疗眼科疾病的药物中的应用。
• Chemical synthesis
  申请人：Kavtaradze Kita Levan

  公开号：US20050038301A1

  公开（公告）日：2005-02-17

  The present invention relates to a method of producing vicinal diols from a compound, the method characterised by the step of reacting the compound with a moderately strong acid in the presence one or more reagents capable of supplying hydroxyl groups wherein the moderately strong acid is a strongly reducing agent, but has a conjugate base that is a weak nucleophile. In preferred embodiments the moderately strong acid is hypophosphorous acid and the reagent(s) capable of supplying hydroxyl groups is 2-propanol in water, where 2-propanol is water soluable and organic. This method is particularly applicable to the production of vicinal diols of steroids, including lanosterol. Once vicinal diols of lanosterol diols are formed they are then capable of being further reacted to produce high purity lanosterol.

  本发明涉及一种从化合物中制备邻二醇的方法，其特征在于将该化合物与中等强度酸在一种或多种能够提供羟基的试剂的存在下反应，其中中等强度酸是一种强还原剂，但具有弱亲核副基。在优选实施例中，中等强度酸是亚磷酸，能够提供羟基的试剂是水中的2-异丙醇，其中2-异丙醇是水溶性和有机的。该方法特别适用于类固醇，包括麦角甾醇的邻二醇的生产。一旦形成了麦角甾醇的邻二醇，它们就能够进一步反应，产生高纯度的麦角甾醇。
• 14,15-Substituted lanosterols and their use as hypocholesterolemic agents
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：EP0276823A2

  公开（公告）日：1988-08-03

  Lanosterols substituted in the 14 and/or 15 position(s) which are active in inhibiting lanosta-8,24-dien-3β-ol 14α-methyl-demethylase activity, supressing 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity, decreasing cholesterol synthesis and reducing serum cholesterol levels are disclosed.

  公开了在 14 和/或 15 位被取代的羊毛甾醇，它们在抑制羊毛甾-8,24-二烯-3β-醇 14α-甲基-脱甲基酶活性、抑制 3-羟基-3-甲基戊二酰辅酶 A 还原酶 (HMGR) 活性、减少胆固醇合成和降低血清胆固醇水平方面具有活性。
• Use of endogenous metabolites for early diagnosing sepsis
  申请人：BIOCRATES Life Sciences AG

  公开号：EP2339352A1

  公开（公告）日：2011-06-29

  The present invention relates to a use of one or a plurality of endogenous target metabolites for predicting a likelihood of an onset of a sepsis from a biological sample of a mammalian subject in vitro, wherein said endogenous target metabolites have a molecular mass less than 1500 Da and are selected from the group of oxysterols.

  本发明涉及使用一种或多种内源性目标代谢物来预测体外哺乳动物生物样本中败血症发生的可能性，其中所述内源性目标代谢物的分子质量小于 1500 Da，并且选自氧甾醇组。